III.a

Alveolar hemorrhage, diffuse (DAH)

(Fr: hémorragie alvéolaire pure, isolée, sans auto-Ac). Diffuse bland alveolar hemorrhage (DAH). Can be severe or fatal (PMID 26236607). When unassociated with pulmonary vasculitis or capillaritis, the condition is named bland diffuse alveolar hemorrhage (DAH). Caution: hemosiderin-laden BAL macrophages can be found in DAD (PMID 19129275). Laboratory clues to this condition include ANA, ANCA, platelets and coagulation studies (INR, and full blood count). DAH may unravel thrombocytopenia, coaculopathy, ANA- or ANCA- and, less often, anti-GBM-related disease. Pulmonary capillaritis is more often suspected than proved, as the lung biopsy is generally avoided if typical BAL features are present. ANCA of MPO-, HNE- or, less often, -PR3 with multispecificity and high titers suggest the drug etiology. Drug-induced DAH can mimic primary ANCA-related micropolyangiitis or 'Wegener's'. See PMID 19592204, 20442117, 21606695, 21674416. A search for underlying pulmonary condition at the origin of hemorrhage (e.g. lung cancer, bronchiectasis) is indicated. See also under IIIb, VId, Xs, Xz, XVIIv. 2018 review @PMID 30404115

Last update : 01/01/1970
 

Causative drugs

151

Abused drugs/substances (illicit-, street drugs - IV/inhaled)

I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis (silicosis, talcosis...)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
IV.g IV - Airway involvement
IV.g - Cough syncope
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.q V - Pleural and/or pericardial involvement
V.q - Empyema
V.ab V - Pleural and/or pericardial involvement
V.ab - Pneumothorax, bilateral
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease
VI.g VI - Pulmonary vasculopathies
VI.g - Foreign body pulmonary vasculopathy (Excipient lung disease)
VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension
VI.j VI - Pulmonary vasculopathies
VI.j - Mercury pulmonary embolism
VI.r VI - Pulmonary vasculopathies
VI.r - Septic pulmonary embolism
VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VII.i VII - Mediastinal involvement
VII.i - Mediastinitis
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic facial and/or airway injury
VIII.ai VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ai - Nasal, palatal and/or pharyngeal pathology
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.s IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.s - Botulism (foodborne-, wound-)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
X.bb X - Systemic/Distant conditions, syndromes and reactions
X.bb - Talc retinopathy
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)
XI.m XI - Miscellaneous
XI.m - Pulmonary emphysema - Lung cysts or bullae
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.i XII - Cardiovascular involvement / toxicity
XII.i - Endocarditis (infective)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XV.q XV - Pathology
XV.q - Path: Foreign body deposits/granulomatous reaction
XV.s XV - Pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP
XV.ag XV - Pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy
XV.al XV - Pathology
XV.al - Path: Pulmonary hypertension incl. angiomatoid vasculopathy
XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules)
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
XVII.s XVII - Infections & related conditions
XVII.s - Sternoclavicular septic arthritis
XVII.u XVII - Infections & related conditions
XVII.u - Epidural abscess
XVII.al XVII - Infections & related conditions
XVII.al - Osteomyelitis (notably of thoracic bones)
XVIII.t XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.t - Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose
XVIII.u XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.u - Eye catcher: Talc retinopathy
2

Adalimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary, extrapulmonary, systemic (ANCA-positive)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.aa XVII - Infections & related conditions
XVII.aa - Coccidioidomycosis
1

Alemtuzumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)
X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
1

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.at I - Interstitial/parenchymal lung disease
I.at - Amiodarone pulmonary toxicity - Amiodarone lung
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.l II - Pulmonary edema - Acute lung injury - ARDS
II.l - Postoperative ARDS
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.t V - Pleural and/or pericardial involvement
V.t - The apical cap
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory depression-Hypoventilation-Bradypnea
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction
X.q X - Systemic/Distant conditions, syndromes and reactions
X.q - Systemic inflammatory response
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain
XI.f XI - Miscellaneous
XI.f - Bluish; pseudocyanotic skin discoloration
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.p XII - Cardiovascular involvement / toxicity
XII.p - QT prolongation
XII.t XII - Cardiovascular involvement / toxicity
XII.t - Torsades de pointe
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina
XII.au XII - Cardiovascular involvement / toxicity
XII.au - Heart failure (thyrotoxicosis-, thyroid storm-mediated)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia (including nodular-) - A LIP-pattern
XV.o XV - Pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.r XV - Pathology
XV.r - Path: Smudged geographic necrosis
XV.ao XV - Pathology
XV.ao - Path: Pleuritis, pleural fibrosis
XV.bt XV - Pathology
XV.bt - Path: Histiocytic proliferation
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.j XVI - Imaging
XVI.j - Imaging: Wandering (migratory) pulmonary opacities
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules
XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
XVI.bq XVI - Imaging
XVI.bq - Imaging: A pattern consistent with pleuroparenchymal fibroelastosis
XVI.bt XVI - Imaging
XVI.bt - Imaging: A subsolid lung nodule or nodules
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT
XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT
XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
XIX.e XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages
XIX.m XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential
XIX.p XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.p - BAL: Lamellar bodies in AM on EM
2

Anabolic androgenic steroids

I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low oxygen saturation (may occur in isolation)
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.x IV - Airway involvement
IV.x - Transient hacking cough
VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic)
XII.v XII - Cardiovascular involvement / toxicity
XII.v - Hypertrophic cardiomyopathy
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XV.bu XV - Pathology
XV.bu - Path: Pulmonary peliosis
1

Anticoagulants, oral (vitamin K antagonists-VKA)

III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
III.e III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.e - Pulmonary hematoma
III.k III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.k - Epistaxis
IV.af IV - Airway involvement
IV.af - Calcification of tracheobronchial cartilaginous rings
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO
VIII.q VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.q - Tongue involvement (edema, hematoma)
VIII.u VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.u - Vocal cord hematoma
VIII.v VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.v - Retropharyngeal hematoma
IX.x IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.x - Thoracic epidural or spinal hematoma
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression)
XI.am XI - Miscellaneous
XI.am - Rectus abdominis hematoma
XII.ar XII - Cardiovascular involvement / toxicity
XII.ar - Calcification of the coronary artery walls or atheroma
XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage
XIX.e XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XXIV.e XXIV - Veterinary medicine
XXIV.e - Veterinary: Tracheal hemorrhage, stenosis, collapse
2

Aspirin (Salicylate-ASA) - Aspirin containing drugs

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal)
V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.y VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.y - Sinonasal discharge, -blockage, -obstruction
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.q X - Systemic/Distant conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea
XI.as XI - Miscellaneous
XI.as - Pharmacobezoar
XI.az XI - Miscellaneous
XI.az - Sneezing (may cause pulmonary barotrauma)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.w XV - Pathology
XV.w - Path: Pulmonary edema (see also II/IIa)
1

Azathioprine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis
I.ah I - Interstitial/parenchymal lung disease
I.ah - Acute restrictive lung dysfunction
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.bq XV - Pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Bevacizumab

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis
III.g III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.g - Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)
III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis
III.k III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.k - Epistaxis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VIII.o VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.o - Perforation of the nasal septum
VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation
VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary, extrapulmonary, systemic (ANCA-positive)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XII.aj XII - Cardiovascular involvement / toxicity
XII.aj - Systemic arterial thrombosis
XII.at XII - Cardiovascular involvement / toxicity
XII.at - Aortitis
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
3

Bortezomib

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD) diffuse, severe. W/wo the features of ARDS
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
1

Breast implants - Augmentation mammaplasty (w/wo evidence for leakage/rupture)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD). Acute, subacute, or chronic
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung'
I.am I - Interstitial/parenchymal lung disease
I.am - Siliconoma
II.u II - Pulmonary edema - Acute lung injury - ARDS
II.u - Acute respiratory failure (ARDS, pulmonary edema, severe bronchospasm) requiring ECMO
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.v V - Pleural and/or pericardial involvement
V.v - Silicone pleural effusion
V.w V - Pleural and/or pericardial involvement
V.w - Silicone pleural nodules - Pleural siliconomas
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.q X - Systemic/Distant conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary, extrapulmonary, systemic (ANCA-positive)
X.ad X - Systemic/Distant conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XIII.f XIII - Neoplastic conditions
XIII.f - Fibromatosis of the chest wall
XIII.h XIII - Neoplastic conditions
XIII.h - Pulmonary nodular lymphoid hyperplasia
XIII.i XIII - Neoplastic conditions
XIII.i - Breast implant-associated anaplastic large cell lymphoma
XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia (including nodular-) - A LIP-pattern
XV.bn XV - Pathology
XV.bn - Path: Silicone droplets/vacuoles in lung tissue, pulmonary vasculature, or lymph nodes
XV.cq XV - Pathology
XV.cq - Path: Silicone lymphadenopathy
XV.cr XV - Pathology
XV.cr - Path: Silicone pleural nodules or siliconoma (See under Vw)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.av XVI - Imaging
XVI.av - Imaging: Displacement/migration of a breast implant
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVIII.c XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.c - Eye catcher: A displaced breast implant
1